Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
12 studies found for:    weill | Open Studies | "Liver Diseases"
Show Display Options
Rank Status Study
1 Recruiting Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment
Condition: Non Alcoholic Steatohepatitis (NASH)
Interventions: Drug: Obeticholic Acid;   Drug: Placebo
2 Recruiting Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
Conditions: Non-alcoholic Steatohepatitis;   Fibrosis;   Liver Diseases
Interventions: Drug: Emricasan (5 mg);   Drug: Emricasan (50 mg);   Drug: Placebo
3 Recruiting Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
Condition: Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Interventions: Drug: Elafibranor;   Drug: Placebo
4 Recruiting Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection
Conditions: HIV-1 Infection;   Hepatitis
Interventions: Drug: Ribavirin;   Drug: Sofosbuvir;   Drug: Ledipasvir/Sofosbuvir
5 Recruiting Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy
Condition: HIV Infections
Interventions: Drug: Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT);   Drug: Dasabuvir (DSV);   Drug: Ribavirin (RBV)
6 Recruiting Study of Oral Treatments for Hepatitis C
Condition: Chronic Hepatitis C
Interventions: Drug: sofosbuvir/ledipasvir;   Drug: ombitasvir/paritaprevir/ritonavir (Phase 1 only);   Drug: elbasvir/grazoprevir;   Drug: Dasabuvir
7 Recruiting HCV-TARGET- Hepatitis C Therapeutic Registry and Research Network
Condition: Hepatitis C
Intervention:
8 Recruiting Phase 3 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cirrhosis
Condition: Liver Cirrhosis, Biliary
Interventions: Drug: Obeticholic Acid (OCA);   Drug: Placebo
9 Recruiting A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)
Condition: Carcinoma, Hepatocellular
Intervention: Drug: RO7070179
10 Recruiting Clinical Performance Evaluation of DxN HBV Assay
Condition: Hepatitis B
Intervention: Diagnostic Test: DxN HBV Assay
11 Recruiting Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
Condition: Unresectable Hepatocellular Carcinoma
Intervention: Device: TheraSphere
12 Recruiting Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
Conditions: Colorectal Cancer;   Gastric Adenocarcinoma;   Esophageal Cancer;   Hepatocellular Carcinoma;   Non-small Cell Lung Cancer;   Small Cell Lung Cancer;   Ovarian Epithelial Cancer;   Carcinoma Breast Stage IV;   Hormone-refractory Prostate Cancer;   Pancreatic Ductal Adenocarcinoma;   Head and Neck Cancers- Squamous Cell;   Renal Cell Cancer;   Urinary Bladder Neoplasms;   Cervical Cancer;   Endometrial Cancer;   Follicular Thyroid Cancer;   Glioblastoma Multiforme
Intervention: Drug: IMMU-132

Study has passed its completion date and status has not been verified in more than two years.